Irish Irish
en Englishaf Afrikaanssq Albanianar Arabichy Armenianaz Azerbaijanieu Basquebe Belarusianbg Bulgarianca Catalanzh-CN Chinese (Simplified)zh-TW Chinese (Traditional)hr Croatiancs Czechda Danishnl Dutchet Estoniantl Filipinofi Finnishfr Frenchgl Galicianka Georgiande Germanel Greekht Haitian Creoleiw Hebrewhi Hindihu Hungarianis Icelandicid Indonesianga Irishit Italianja Japaneseko Koreanlv Latvianlt Lithuanianmk Macedonianms Malaymt Malteseno Norwegianfa Persianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsw Swahilisv Swedishth Thaitr Turkishuk Ukrainianur Urduvi Vietnamesecy Welshyi Yiddish

Nuacht is Déanaí

Fógraíonn BioMarin Éifeachtúlacht Haemastatach Bhuan a Chothabháil Thar 6 bliana i Staidéar Leanúnach Céim 1/2 ar Valoctocogene Roxaparvovec, Teiripe Géine Imscrúdaithe do Haemaifilia A

Fógraíonn BioMarin Éifeachtúlacht Haemastatach Bhuan a Chothabháil Thar 6 bliana i Staidéar Leanúnach Céim 1/2 ar Valoctocogene Roxaparvovec, Teiripe Géine Imscrúdaithe do Haemaifilia A
Úsáideoir Super
Úsáideoir Super
Ar ais go barr
Íomha

Please enable the javascript to submit this form

Maidir

Le tacaíocht ó dheontais oideachais ó Bayer, BioMarin, CSL Behring, Freeline Therapeutics Limited, Pfizer Inc., Spark Therapeutics, agus uniQure, Inc.

Riachtanach SSL